2011年 · 第31卷第12期

The efficacy and adverse effects of traditional treatment of Crohn's disease (CD) need to be improved. Infliximab (IFX), known under the trade name Remicade, is an anti-tumor necrosis factor (TNF) -α human-mouse chimeric IgG1 monoclonal antibody, which plays a therapeutic role by antagonizing the pro-inflammatory factor TNF-α, which plays a key role in the pathway of CD immune inflammation. IFX is the first new biologic officially used for CD treatment and has been used around the world for more than a decade. With the advancement of research, the international consensus opinion on its application in inflammatory bowel disease (IBD) has been revised several times. China's State Food and Drug Administration (SFDA) officially approved the drug for CD treatment in 2007. Chinese doctors have gradually accumulated some experience in the use of this drug. In view of the fact that the recommended scheme of IFX for the treatment of CD formulated in 2008 in China is no longer suitable for the current level of understanding, the Inflammatory Bowel Disease Group of Gastroenterology Branch of Chinese Medical Association recently organized relevant experts to discuss the revision of the recommended scheme, and extensively solicited the opinions of the members of the group. The 2011 revision of the recommended protocol for IFX in the treatment of Crohn's disease is hereby presented below.

Biologics have revolutionized the treatment of inflammatory bowel disease (IBD). However, not all patients require biological therapy. Patient screening depends on clinical characteristics, previous responses to other treatments, and complications. Effective guidelines and patient screening protocols can guide the choice of first-line biological therapy for patients with Crohn's disease (CD). In terms of evidence-based data, Inflixi (IFX) clinical studies have the most evidence. Other biologics [adamu (ADA), certuzul (CZP), natalizul (NAT)] also showed similar efficacy for CD.